Tumor Reduction with Pazopanib in a Patient with Recurrent Lumbar Chordoma by Maurício Fernando Silva Almeida Ribeiro, Micelange Carvalho de Sousa, Samir Abdallah Hanna, Marcos Vinicius Calfat Maldaun, Ceci Obara Kurimori, Luiz Guilherme Cernaglia Aureliano de Lima, Romulo Loss Mattedi, Rodrigo Ramella Munhoz

“…A large proportion of these tumors express stem-cell factor receptor (c-KIT) and platelet-derived growth factor receptors (PDGFRs), providing a rationale for the use of tyrosine-kinase inhibitors (TKIs). Case report. A 27-year-old male presented with recurrent chordoma of the lumbar spine 4 years after initial diagnosis. …”
Get full text

Molecular Mechanisms and Therapeutic Prospects of Immunotherapy and Targeted Therapy in Primary Central Nervous System Lymphoma by Lin Zhong MM, Anqing Lu MB, Xiyue Lu MM, Xiaoyin Liu MD, Lujia Cao MM, Shihong Zhu MM, SiJun Diao MM, Xu Cheng MM, Hongwei Wu MB, Jing Chen MD

“…With a deeper understanding of the pathophysiology of PCNSL, various therapies, including CD20 monoclonal antibodies, Bruton's tyrosine kinase (BTK) inhibitors, immunomodulatory drugs, immune checkpoint inhibitors, phosphoinositide 3-kinase (PI3 K)/mammalian target of rapamycin(mTOR) inhibitors, and chimeric antigen receptor (CAR) -T cells are increasingly being applied and have demonstrated considerable efficacy. …”
Get full text

Optimal Molecular Methods in Detecting p190BCR-ABL Fusion Variants in Hematologic Malignancies: A Case Report and Review of the Literature by Rebecca J. Sonu, Brian A. Jonas, Denis M. Dwyre, Jeffrey P. Gregg, Hooman H. Rashidi

“…Patients with BCR-ABL1 positive hematologic malignancies and Philadelphia-like B-lymphoblastic leukemia (B-ALL) are potential candidates for targeted therapy with tyrosine kinase inhibitors (TKI). Before TKIs, patients with B-ALL had a much worse prognosis and current treatments with targeted TKI therapy have improved outcomes. …”
Get full text

Enhancing immunotherapy efficacy in colorectal cancer: targeting the FGR-AKT-SP1-DKK1 axis with DCC-2036 (Rebastinib) by Xiguang Chen, Qiting Zeng, Liyang Yin, Bingru Yan, Chen Wu, Jianbo Feng, Ying Wu, Jun He, Wenjun Ding, Jing Zhong, Yingying Shen, Xuyu Zu

“…Abstract This research demonstrates that DCC-2036 (Rebastinib), a potent third-generation tyrosine kinase inhibitor (TKI), effectively suppresses tumor growth in colorectal cancer (CRC) models with functional immune systems. …”
Get full text

Myeloid Neoplasms with t(5;12) and ETV6-ACSL6 Gene Fusion, Potential Mimickers of Myeloid Neoplasm with PDGFRB Rearrangement: Case Report with Imatinib Therapy and Review of the Li... by Javier De Luca-Johnson, Jose I. Ruades Ninfea, Lauren Pearson, Joanna Conant, Ronald Bryant, Neil A. Zakai, Mary E. Tang

“…In particular, while tyrosine kinase inhibitor therapy is effective in patients with PDGFRB rearrangement, there is little information on imatinib efficacy in patients with ETV6-ACSL6 gene fusion. …”
Get full text

Aberrant heterochromatin silences immune response genes in chronic lymphocytic leukemia by Olivia M. Depies, Qianqian Guo, Yuan Gao, Sutapa Sinha, Zhenqing Ye, Weiguo Han, Kari G. Rabe, Mingma S. Hoel, Heather C. Darby, Chuanhe Yu, Esteban Braggio, Sameer A. Parikh, Susan L. Slager, Neil E. Kay, Zhiquan Wang

“…Finally, when treated with the Bruton tyrosine kinase inhibitor ibrutinib, these silenced enhancers are relatively stable during therapy compared with the CLL-gained enhancers. …”
Get full text

Esophageal Gastrointestinal Stromal Tumor with Rare Intracranial Metastasis by José Carvalho, Margarida Teixeira, Francisco Teixeira Silva, Alexandra Esteves, Carlos Ribeiro, Diana Guerra

“…Our patient lived for 13 years with excellent disease control with imatinib, but the fact that it does not cross the blood-brain barrier makes it not useful in preventing or treating brain lesions. New tyrosine kinase inhibitors that may cross the blood-brain barrier could be the answer to these cases.…”
Get full text

Determination of Crizotinib in Mouse Tissues by LC-MS/MS and Its Application to a Tissue Distribution Study by Fang Zhao, Yuan Wei, Yiming Yan, Han Liu, Sitong Zhou, Bo Ren, Ruijuan Liu

“…Toxicity induced by crizotinib, a small-molecule tyrosine kinase inhibitor, is a significant clinical issue during treatment. …”
Get full text

Enhanced ferroptosis sensitivity promotes the formation of highly myopic cataract via the DDR2-Hippo pathway by Dongling Guo, Yu Du, Xin Liu, Dan Li, Ling Wei, Xiangjia Zhu

“…Mechanistically, RNA sequencing of HMC lens epithelial samples identified up-regulated expression of discoidin domain receptor tyrosine kinase 2 (DDR2) as a key factor, which could enhance ferroptosis sensitivity via the Src-Hippo pathway. …”
Get full text

Characterization of covalent inhibitors that disrupt the interaction between the tandem SH2 domains of SYK and FCER1G phospho-ITAM. by Frances M Bashore, Vittorio L Katis, Yuhong Du, Arunima Sikdar, Dongxue Wang, William J Bradshaw, Karolina A Rygiel, Tina M Leisner, Rod Chalk, Swati Mishra, C Andrew Williams, Opher Gileadi, Paul E Brennan, Jesse C Wiley, Jake Gockley, Gregory A Cary, Gregory W Carter, Jessica E Young, Kenneth H Pearce, Haian Fu, Emory-Sage-SGC TREAT-AD Center, Alison D Axtman

“…RNA sequencing and genetic data support spleen tyrosine kinase (SYK) and high affinity immunoglobulin epsilon receptor subunit gamma (FCER1G) as putative targets to be modulated for Alzheimer's disease (AD) therapy. …”
Get full text

Detection of The TNFSF Members BAFF, APRIL, TWEAK and Their Receptors in Normal Kidney and Renal Cell Carcinomas by Vassiliki Pelekanou, George Notas, Katerina Theodoropoulou, Marilena Kampa, Dimitrios Takos, Vassilia-Ismini Alexaki, Jelena Radojicic, Frank Sofras, Andreas Tsapis, Efstathios N. Stathopoulos, Elias Castanas

“…Therapeutic modalities targeting VEGF, PDGF, and c-kit using tyrosine kinase inhibitors and m-TOR using specific biologic factors are in development. …”
Get full text

New therapies in pulmonary arterial hypertension: Recent insights by Giulia Guglielmi, Konstantinos Dimopoulos, S. John Wort

“…Subsequent sections describe treatments that target epigenetic regulators, e.g. poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors and direct BRD4 antagonists, tyrosine kinase inhibitors (Seralutinib), and therapies aimed at inflammation, such as IL-6 inhibitors, CD-20 inhibitors, and monoclonal antibodies that prevent macrophage migration. …”
Get full text

Cytokine-armed oncolytic herpes simplex viruses: a game-changer in cancer immunotherapy? by Howard L Kaufman, Hongbin Wang, Dipongkor Saha, Samuel D Rabkin, Mia Borlongan, Uyen Le, Hans J Nauwynck

“…In this review, we highlight preliminary data with several cytokines and chemokines, including GM-CSF, interleukin 12, FMS-like tyrosine kinase 3 ligand, tumor necrosis factor α, interleukin 2, interleukin 15, interleukin 18, chemokine (C-C motif) ligand 2, chemokine (C-C motif) ligand 5, chemokine (C-X-C motif) ligand 4, or their combinations, and show how these payloads can further enhance the antitumor immunity of oHSV. …”
Get full text

Metastatic brain tumors: from development to cutting‐edge treatment by Guilong Tanzhu, Liu Chen, Jiaoyang Ning, Wenxiang Xue, Ce Wang, Gang Xiao, Jie Yang, Rongrong Zhou

“…For lung cancer, targeted therapy and immunotherapy have shown efficacy, while in breast cancer, monoclonal antibodies, tyrosine kinase inhibitors, and antibody–drug conjugates are effective in BM. …”
Get full text

Angiogenic Factors and Renal Disease in Pregnancy by Julie S. Rhee, Brett C. Young, Sarosh Rana

“…Prior studies show that there is an angiogenic factor imbalance with elevated levels of antiangiogenic proteins soluble fms-like tyrosine kinase 1 (sFlt1) and soluble endoglin (sEng) and reduced levels of the proangiogenic protein, placental growth factor (PlGF) in women with preeclampsia. …”
Get full text

HSP90 inhibitors promote cell death by degrading Met and BCR::ABL1 in both imatinib-resistant and -sensitive chronic myeloid leukemia cells by Masanobu Tsubaki, Taira Matsuo, Rie Komori, Noriaki Nagai, Tetsushi Yamamoto, Shozo Nishida

“…Abstract Background Chronic myeloid leukemia is associated with a more favorable prognosis following treatment with BCR::ABL1 tyrosine kinase inhibitors (TKIs). Nonetheless, about 40% of affected individuals with CML display resistance or intolerance towards BCR::ABL1 TKIs. …”
Get full text

The Mechanisms of Systemic Inflammatory and Immunosuppressive Acute-on-Chronic Liver Failure and Application Prospect of Single-Cell Sequencing by Kai Kou, Xiaodong Sun, Guangyao Tian, Yao Zhi, Zhongqi Fan, Guoyue Lv

“…In this process, the dysfunction of monocyte and macrophage is reflected in the downregulation of HLA-DR and upregulation of MER tyrosine kinase (MERTK), which weakens the antigen presentation function and reduces the secretion of inflammatory cytokines. …”
Get full text

Consensus guidelines for the management of treatment-naïve chronic lymphocytic leukaemia in Singapore (2024) by Yeow Tee Goh, Yvonne Loh, Esther Chan, Yuh Shan Lee, Venkata Sreekanth Sampath, Daryl Tan, Shin Yeu Ong, Chandramouli Nagarajan

“…Due to the superior efficacy of targeted agents (Bruton's tyrosine kinase inhibitors [BTKis] and B-cell lymphoma 2 inhibitors [BCL2is]), sthese are favoured over standard chemotherapy or chemotherapy-immunotherapy, especially for patients with del(17p) or TP53 mutation, and less fit patients. …”
Get full text

Current preeclampsia prediction model and biomarker by Anak Agung Ngurah Jaya Kusuma

“…Additionally, biomarkers like mean arterial pressure (MAP), UtA-PI, and the ratio of soluble fms-like tyrosine kinase-1 to placental growth factor (sFlt-1/PlGF) are employed to improve predictive accuracy. …”
Get full text

Clinical advances in antibody-drug conjugates for hematological malignancies by TANG Sijie, MI Jianqing

“…Additionally, ADCs targeting different antigens such as CD123, CD19, CD20, receptor tyrosine kinase-like orphan receptor 1 (ROR1), and CD38 are undergoing clinical studies. …”
Get full text